German specialty life sciences company Revive Therapeutics Ltd has reportedly inked a sponsored research agreement with University of California, San Francisco (UCSF). This agreement is geared towards exploring the potential of Bucillamine as a treatment for COVID-19.
This deal is expected to support the research in the laboratory of Dr. John Fahy for testing Bucillamine’s efficacy in pre-clinical models of COVID-19. It will also involve designing of protocols that test the utility of Bucillamine for human trials.
CEO of Revive, Michael Frank stated that the company is looking forward to expanding Bucillamine’s utility as a potential treatment for severe COVID-19 through the research agreement with UCSF wherein Dr. John Fahy is the principal Investigator.
Frank also added that studying Bucillamine for severe COVID-19 combined with Revive’s dedication towards concluding its ongoing Phase 3 clinical study on mild-to-moderate COVID-19, will place Bucillamine as a potential oral treatment for mild-moderate to severe COVID-19.
Revive is however, not making any implied claims that its product can eliminate or cure COVID-19 (SARS-2 Coronavirus) at present.
Dr. Fahy is reportedly the senior author of a recent study that shows that thiol-based drugs such as Bucillamine, reduce the binding of SARS-CoV-2 spike protein with its receptor, reduce SARS-CoV-2 spike pseudotyped virus’s entry efficiency, and prevents infection caused by SARS-CoV-2 live virus. These findings apparently uncovered SARS-CoV-2’s vulnerability to thiol-based drugs and offer rationale for testing thiol-based drugs like Bucillamine as a novel treatment for COVID-19.
For the records, Dr. John Fahy, MD, MSc is Professor of Medicine in Pulmonary and Critical Care Medicine Division and the Department of Medicine at UCSF. He is also the director of UCSF’s severe asthma clinic. Dr. Fahy also directs the Airway Clinical Research Center at UCSF. His research is funded by the National Institutes of Health for the studies of lung disease and for studying thiol-based drugs for treating mucus pathology in the lung.
Source credits: http://www.globenewswire.com/news-release/2021/05/03/2221464/0/en/Revive-Therapeutics-Enters-Into-Research-Agreement-with-UCSF-For-Bucillamine-As-Potential-Treatment-For-Severe-COVID-19.html